Follistatin-344 alternatives.
10 compounds compared to Follistatin-344, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Follistatin-344 is sold in gray-market channels as a research peptide, and that is a category error worth catching before you compare anything. FS-344 is the transgene delivered in AAV gene-therapy programs, not an injectable peptide product, and the isoform was chosen partly to reduce off-target heparin and cell-surface binding. It holds no approval from any major regulator for any indication. People searching for alternatives generally want myostatin-pathway inhibition in a form they can obtain, and the honest answer is that the field has none: ACE-031 reached human trials and was stopped for safety, and no myostatin inhibitor is approved. WADA covers this category as well.
Follistatin-344 (FS-344) is an alternatively spliced isoform of human follistatin, a naturally occurring secreted glycoprotein that acts as a high-affinity antagonist of several TGF-beta superfamily ligands.
- 01ACE-031D tierIn human trialsramatercept · ActRIIB-Fc
Acts through the myostatin and activin receptor inhibition pathway, like Follistatin-344. In human trials.
- 02
- 03
- 04SermorelinC tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 05GHRP-1D tierResearch / preclinicalgrowth hormone-releasing peptide-1
Same category: growth hormone. Research / preclinical.
- 06GHRP-2D tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 07GHRP-6D tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 08HexarelinD tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 09CJC-1295F tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 10IGF-1 LR3F tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
An “alternative” here means a compound that shares Follistatin-344's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.